menu
    • menu

    Company profile for Averitas Pharma

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Averitas Pharma was formed in 2018 as the USA commercial subsidiary of The Grünenthal Group, a multinational pharmaceutical company headquartered in Germany with a presence in more than 30 countries across Europe, Latin America and the USA. For more than 70 years, Grünenthal has been a global leader in the research and development of therapeutics for pain, gout and inflammation. The first innovative product in our portfolio ...
    Averitas Pharma was formed in 2018 as the USA commercial subsidiary of The Grünenthal Group, a multinational pharmaceutical company headquartered in Germany with a presence in more than 30 countries across Europe, Latin America and the USA. For more than 70 years, Grünenthal has been a global leader in the research and development of therapeutics for pain, gout and inflammation. The first innovative product in our portfolio is Qutenza® (capsaicin) 8% patch, a non-opioid, which was acquired in late 2018.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Averitas PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    360 Mt. Kemble Ave. 3rd FL, Ste 3 Morristown, NJ 07960
    Telephone
    Telephone
    908-393-0047
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.averitaspharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Grünenthal & Averitas Recruits for QUTENZA® Ph 3in Neuropathic Pain
    Grünenthal & Averitas Recruits for QUTENZA® Ph 3in Neuropathic Pain

    07 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with-qutenza-in-post-surgical-neuropathic-pain-302298768.html

    PR NEWSWIRE
    07 Nov 2024
    Share Share
    Veritas Collaborative Partners With Project HEAL to Make Large-Scale Commitment
    Veritas Collaborative Partners With Project HEAL to Make Large-Scale Commitment

    14 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/14/2516028/0/en/Veritas-Collaborative-Partners-With-Project-HEAL-to-Make-Large-Scale-Commitment-to-Equitable-Eating-Disorder-Treatment-Access-in-Atlanta.html

    GLOBENEWSWIRE
    14 Sep 2022
    Share Share
    Grünenthal and Averitas Pharma announce initiation of Phase III study
    Grünenthal and Averitas Pharma announce initiation of Phase III study

    30 Mar 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/grunenthal-and-averitas-pharma-announce-initiation-of-phase-iii-study-with-qutenza-to-prepare-label-extension-in-the-us-for-the-treatment-of-post-surgical-neuropathic-pain-301258564.html

    PRNEWSWIRE
    30 Mar 2021
    Share Share
    Growth for Grünenthal with new Qutenza indication
    Growth for Grünenthal with new Qutenza indication

    22 Jul 2020

    // THEPHARMALETTER

    https://www.thepharmaletter.com/article/growth-for-grunenthal-with-new-qutenza-indication

    THEPHARMALETTER
    22 Jul 2020
    Share Share
    Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA®
    Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA®

    21 Jul 2020

    // GRUNENTHAL

    https://www.grunenthal.com/en/press-room/press-releases/us-fda-approval-of-qutenza-for-the-treatment-of-neuropathic-pain-associated-with-dpn-of-the-feet

    GRUNENTHAL
    21 Jul 2020
    Share Share
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)
    Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)

    18 Dec 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/averitas-pharma-announces-fda-acceptance-of-snda-filing-for-qutenza-capsaicin-8-patch-for-the-treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-300976908.html

    PR NEWSWIRE
    18 Dec 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search